NEWS
STRATA Skin Sciences Pre-Announces Second Quarter 2024 Financial Results
Positive
Estimated Q2 2024 revenue between $8.0 million and $8.4 million.
Growth in the domestic installed base of TheraClear®X devices from 104 to 117 units.
Cash, cash equivalents, and restricted cash of $6.8 million.
Strategic initiatives to drive device utilization and direct-to-consumer activities.
Increased media coverage potentially enhancing market awareness.
Negative
Decline in the domestic installed base of XTRAC® devices from 907 to 881 units.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1036Followers
64Following
6987Visitors
Follow